Wednesday, March 3, 2021

UK to trial if different jabs combined over 2 shots more effective

The trial will first examine immune responses of a dose of Pfizer vaccine followed by a booster of AstraZeneca’s.

Other News

Suaram kecam gesaan sektor swasta tawarkan vaksin Covid-19

Kumpulan hak asasi itu berkata pengkomersilan vaksin akan menguntungkan orang kaya dan menggalakkan potong barisan dalam program vaksinasi.

Rights group slams call for private hospitals to offer Covid-19 jabs

Suaram says any commercialisation of the vaccines will lead to another form of queue-cutting that will benefit the rich.

TMJ eyeing Spanish football club Valencia?

The club was valued at €408 million in a report by global accountancy firm KPMG last year.

AirAsia perkenal ‘Asean Unlimited’ tawar khidmat penghantaran

AirAsia Group Bhd memanfaatkan perkembangan vaksinasi Covid-19 dengan memperkenalkan produk terbaharu - ‘Asean Unlimited’ yang menawarkan pas penerbangan antarabangsa dan domestik serta perkhidmatan penghantaran...

Use of tracking device among new provisions under emergency ordinance

The wristband will be made mandatory for those who test positive for Covid-19, persons under investigation and those under surveillance.

Britain has launched a trial to assess the immune responses generated if doses of the Covid-19 vaccines from Pfizer and AstraZeneca are given in a two-shot schedule.

The British researchers behind the trial said on Thursday data on vaccinating people with the two different types of coronavirus vaccines could help understanding of whether shots can be rolled out with greater flexibility around the world

The trial will examine the immune responses of an initial dose of Pfizer vaccine followed by a booster of AstraZeneca’s, as well as vice versa, with intervals of four and 12 weeks.

Both the mRNA shot developed by Pfizer and Biontech and the adenovirus viral vector vaccine developed by Oxford University and AstraZeneca are currently being rolled out in Britain, with a 12-week gap between two doses of the same vaccine.

AstraZeneca’s shot is also being tested in combination with Russia’s Sputnik V vaccine, and it is expected more vaccines will be added to the trial when they are approved and rolled out.

“This is a hugely important clinical trial that will provide us with more vital evidence on the safety of these vaccines when used in different ways,” said Nadhim Zahawi, the designated minister for Covid-19 vaccine deployment in the UK.

Recruitment for the study starts on Thursday, with over 800 participants expected to take part, the researchers said. That makes it much smaller than the clinical trials that have been used to determine efficacy of the vaccines individually.

The trial is recruiting people over the age of 50 who may be at higher risk than younger people and have not been vaccinated already.

Matthew Snape, an Oxford vaccinologist who is leading the trial, said initial results could inform vaccine deployment in the second half of the year.

“We’ll get some results through by June that will inform the use of booster doses in the general population,” he told reporters.

Given the possibility of vaccine supply constraints, data that could support a more flexible immunisation programme would be an advantage, said Jonathan Van-Tam, the UK’s deputy chief medical officer, who is responsible for the study.

“It is also even possible that by combining vaccines, the immune response could be enhanced giving even higher antibody levels that last longer.”

Follow us on Telegram for the latest updates: https://t.me/malaysianow

Subscribe to our newsletter

To be updated with all the latest news and analyses.

Related Articles

Rights group slams call for private hospitals to offer Covid-19 jabs

Suaram says any commercialisation of the vaccines will lead to another form of queue-cutting that will benefit the rich.

Use of tracking device among new provisions under emergency ordinance

The wristband will be made mandatory for those who test positive for Covid-19, persons under investigation and those under surveillance.

Air cargo traffic recovers to pre-pandemic levels

But passenger traffic, measured as revenue per passenger kilometre, was down by 72% in January from the same month last year.

New cases inch lower to 1,555

2,528 recoveries, six more deaths.

MCO states to come under CMCO

Inter-district travel will also be allowed although the ban on interstate travel remains.